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INTRODUCTION
Breast cancer has become the second most frequent cause 
of female deaths and the major causes of treatment failure and/
or death are tumor invasion and metastasis in Europe.
Recent concepts for cancer development suggest that a       
minority population of cancer stem-like cells (CSCs) may     
determine the biologic behavior of tumors [1-3], including     
response to therapy [4]. Recently it was demonstrated a con-
sistent presence of CSCs in residual breast cancers after both 
neoadjuvant chemotherapy, and endocrine therapy [5].
The initial reports about breast cancer stem cells described 
the use of CD44
+CD24
−/low cell-surface antigen signature to 
select CSCs [6,7]. However, recent data show the detection of 
a CD44
+CD24
−/low subpopulation in only 31% of 240 human 
breast cancer samples analyzed, with a strong association with 
the basal-like phenotype [8]. Moreover, it was recently shown 
that CD44
+CD24
−/low phenotype detection is not sufficient, 
alone, to characterize breast CSCs [9].
Cancer stem cell research has recently included Prominin-1, 
CD133, a pentaspan transmembrane glycoprotein with a       
molecular weight of 120 kDa, that was initially considered to 
be a marker of hematopoietic stem cells [10-12]. Recently it 
has been reported the detection of CD133, PAX2, ESA, and 
GPR30 expression in invasive ductal breast carcinomas [13] 
and it was shown, mainly in triple-negative invasive ductal 
breast carcinoma patients, that the expression of CD133       
protein could be correlated with tumor size, metastasis of the 
axillary lymph nodes and the clinical stage [14]. 
In all cases it was documented that the percentage of stem 
cells selected by CSCs markers immunostaining varies gener-
ally from 2% to 40% and is strongly connected to grade and 
aggressiveness [15]. 
In this paper we have identified a low grade tubulolobular 
variant of breast cancer showing an aberrant expression of 
prominin-1 marker. The hyperexpression of CD133 was eval-
uated by flow cytometry analysis, confirmed by immunohis-
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Purpose: Prominin1/CD133 has become the ideal marker for 
cancer stem cells (CSCs) detection in human tumors. In this 
study we examined the expression of this marker in several 
breast cancer specimens to associate CSCs percentage with 
risk factor for this neoplasia. Methods: We examined specimens 
from 12 patients using CD133 and CD44 antibodies for CSCs 
immunohistochemistry detection and for flow cytometry analysis. 
For each patient, we also performed the immunohistochemical 
staining to evaluate the expression of estrogen receptor, proges-
terone receptor, c-erbB-2, Ki67, and E-cadherin markers. A Taq-
man probe for CD133 was used for mRNA quantification by real-
time polymerase chain reaction. Results: Prominin-1 expression 
was heterogeneous in different carcinomas but was strikingly 
hyperexpressed in a tubulolobular variant of breast cancer. The 
results were confirmed by all three methods. Conclusion: Our 
data, although produced on a limited number of samples, showed 
an particularly high expression of stem cell marker CD133 in a 
breast cancer variant, generally with a good prognosis. Since CSCs 
detection by CD133 has been described as an important prog-
nostic factor for several human cancers, we suggest the impor-
tance of detecting stem cell compartiments in all histotypes of 
breast carcinomas.
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tochemistry and for gene expression by quantitative real-time 
polymerase chain reaction (PCR).
METHODS
Patients and specimens
Twelve patients, of which 5 underwent mastectomy for treat-
ment of invasive ductal breast and 7 underwent quadrantec-
tomy during March/April 2011 at the National Cancer Institute 
“Giovanni Pascale” of Neaples were enrolled in this study. We 
also selected 8 tubulolobular variants from our archive of par-
affin samples. All cases were reviewed according to World 
Health Organization classification criteria, using standard     
tissue sections and appropriate immunohistochemical slides.
Medical records were reviewed for clinical information,     
including histologic parameters were determined from the 
H&E-stained slides. Clinicopathologic parameters evaluated 
for each tumor included patient age at initial diagnosis; tumor 
size; histologic subtype; histologic grade; nuclear grade; nodal 
status; number of positive lymph nodes; tumor stage; tumor 
recurrence or distant metastasis; type of surgery. 
Moreover, all specimens were characterized for all routine 
diagnostic immunophenotipic parameters.
Flow cytometric analysis
The fresh tissue obtained from surgery was disaggregated 
mechanically and immediately tested by flow cytometry. The 
cell suspension obtained was counted and washed in PBS 1x. 
At least 200,000 cells were incubated with 1 µg/mL of fluores-
cent-labelled monoclonal antibodies and respective isotype 
controls at 4°C in the dark room. After washing steps, the         
labelled cells were analyzed by flow cytometry using Facs ARIA 
II (Becton & Dickinson, Mountain View, USA). The antibod-
ies used were: CD44 FITC conjugated, CD326 PE conjugated, 
all provided by BD Pharmingen, Buccinasco, Italy, and CD133/ 
2PE mouse anti-Human CD133 (Miltenyi Biotec Inc., Auburn, 
USA). All data were analyzed using a CellQuest software (BD 
Biosciences, San Jose, USA).
Immunohistochemical analysis 
For each patient, immunohistochemical staining was done 
on 7 slides from formalin-fixed, paraffin embedded tissues, to 
evaluate the expression of CD133, estrogen receptor (ER), 
progesterone receptor (PR), c-erbB-2, Ki67, E-cadherin, and 
CD44 markers. Paraffin slides were then deparaffinized in     
xylene and rehydrated through graded alchols. Antigen retrieval 
was performed with slides heated in 0.01 M citrate buffer (pH 
6.0 for CD133, PR, c-erbB-2, Ki67, E-cad, CD44) or Tris-EDTA 
(pH 9 for ER) in a bath for 20 minutes at 97ºC. After antigen 
retrieval, the slides allow to cool. The slides were rinsed with 
TBS and the endogenous peroxidase was inactivated with 3% 
hydrogen peroxide. After protein block (BSA 5% in PBS 1x), 
the slides were incubated with primary antibody to human 
CD133 (Myltenyi Biotec CD133/1 [AC 133] pure human 1:150) 
for 1 hour, and to human ERα (DAKO Monoclonal Mouse 
Anti-Human ERα Clone ID5 1:35), PR (DAKO Monoclonal 
Mouse Anti-Human PR Clone 636 1:50), c-erbB-2 (DAKO 
Polyclonal Rabbit Anti-Human Oncoprotein 1:300), Ki67 
(DAKO Monoclonal Mouse Anti-Human Ki67 Ag Clone 
MIB-1 1:75), CD44 (Novocastra Lyophilized Mouse Mono-
clonal Antibody CD44 Variant 3, 1:35) for 30 minutes and       
to human E-cad (DAKO Monoclonal Mouse Anti-Human     
E-cadherin Clone NCH-38 1:75) for 20 minutes. The sections 
were rinsed in TBS and incubated for 20 minutes with Novo-
castra Biotinylated Secondary Antibody (RE7103), a biotin-
coniugated secondary antibody formulation that recognized 
mouse and rabbit immunoglobulins. Then the sections were 
rinsed in TBS and incubated for 20 minutes with Novocastra 
Streptavidin-HRP (RE7104) and then peroxidase reactivity was 
visualized using a 3,3’-diaminobenzidine (DAB). Finally, the 
sections were counterstained with hematoxylin and mounted. 
Results are interpreted using a light microscope.
Evaluation of immunohistochemistry
Antigen expression was evaluated independently by two 
pathologists (M.DB. and G.B.) using light microscopy. Observers 
were unaware of the clinical outcome. For each sample, at least 
five fields (inside the tumor and in the area exhibiting tumor 
invasion, 400×400) and >500 cells were analyzed. Using a 
semiquantitative scoring system microscopically and referring 
to each antigen scoring method in other studies, two observers 
evaluated the intensity, extent and subcellular distribution of 
CD133, CD44, E-cad, ER, PR, c-erbB-2, and Ki67. In scoring 
CD133, CD44, and E-cad proteins expression, both the extent 
and intensity of immunopositivity in the cell membrane and 
cytoplasm were considered. The cutoff used to distinguish 
‘positive’ from ‘negative’ cases was ≥1% ER/PR positive tumor 
cells. Immunohistochemical analyses of c-erbB-2 expression 
describe the intensity and staining pattern of tumor cells. Only 
membrane staining intensity and pattern were evaluated using 
the 0 to 3+ score as illustrated in the HercepTest kit scoring 
guidelines. The FDA-recognized test, the Herceptest
TM (DAKO), 
describes four categories: no staining, or weak staining in fewer 
than 10% of the tumor cells (0); weak staining in part of the 
membrane in more than 10% of the tumor cells (1+); complete 
staining of the membrane with weak or moderate intensity in 
more than 10% of the neoplastic cells (2+); and strong stain-
ing in more than 10% (3+). Scores of 0 or 1+ were considered Prominin1inTubulobularBreastCarcinoma 17
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negative for HER2/neu-expression, 2+ was uncertain, and 3+ 
was positive. Cases 2+ undergo fluorescence in situ hybridiza-
tion analysis.
RNA extraction and analysis
Total RNA was isolated from frozen biopsies, from our         
Institutional Bio-Bank, using RNeasy Mini Kit (Qiagen GmbH, 
Hilden, Germany) following the manufacturer’s instructions. 
Samples were treated with RNase-free DNase (Qiagen GmbH) 
to prevent amplification of genomic DNA. A total of 1 μg RNA 
was subjected to cDNA synthesis for 1 hour at 37°C using the 
Ready To Go You-Primer First-Strand Beads kit (cod. 27-9264-
01; Amersham Biosciences Europe GmbH, Freiburg, Germany) 
in a reaction mixture containing 0.5 μg random hexamers 
(GeneAmp RNA PCR Random Hexamers Set N808-0127; 
Applied Biosystems, Foster City, USA).
Real-time PCR
Quantitative RT-PCR was performed in a LightCycler system 
(Roche Molecular Biochemicals, Mannheim, Germany) using 
TaqMan
® analysis. In this system, all reactions were run in glass 
capillaries with The LightCycler TaqMan Master Mix (cod. 
04735536001; Roche Molecular Biochemicals), 10 μL, in a vol-
ume of 20 μL containing 2 μL of cDNA and 1 μL of specific 
TaqMan Gene Expression Assays for human CD133 (RealTime 
Designer Assay cod. 05583055001; Roche Molecular Biochem-
icals), according to the manufacturer’s directions. All reactions 
were performed in triplicate. The thermal cycling conditions 
included a step of 20 seconds at 95°C followed by a 40 cycles 
of 95°C for 1 second and 60°C for 20 seconds. The compara-
tive Ct method was employed to determine the human CD133 
gene variation, using as reference gene TaqMan Endogenous 
Controls Human ACTB (β-actin) Endogenous Control (Real-
Time Designer Assay cod. 05532957001; Roche Molecular 
Biochemicals). We identified a calibrator cell line that repre-
sents the unitary amount of the target of interest, consequent-
ly the samples express n-fold mRNA relative to the calibrator. 
Final amounts of target were determined as follows: target 
amount=2−Ct, where Ct=[Ct (CD133)−Ct (ACTB)]sample−[Ct 
(CD133)−Ct (ACTB)]calibrator.
Statistical analysis
The association between CD133 expression with other clin-
icopathological parameters was conducted using the κ
2 and T 
Student’s test. 
The Pearson κ
2 test was used to determine whether a rela-
tionship exists between the variables included in the study. The 
level of significance was defined as p<0.05. All the statistical 
analyses were carried out using the SPSS version 8.0 software 
(SPSS Inc., Chicago, USA).
RESULTS
Clinicopathological characteristics of breast cancer patients 
and tumors 
In our casuistry of fresh tissues are included 12 samples of 
breast cancers, 10 invasive ductal breast carcinomas (83.3%), 
1 lobular breast carcinoma (8.3%), and 1 tubulolobular breast 
carcinoma (8.3%). 
After, we selected 8 tubulolobular variants cases from our 
archive of paraffin samples. 
The age of the breast cancer patients ranged 27-85 years, 
with an average of 52 years. Tumors larger than 2 cm were 
present in 30% (4/20) of patients and lymphatic metastasis 
was found in 40% (8/20) of patients at operation. Thirty-five 
percent (7/20) of tumors were graded as grade 3, 25% (5/20) 
as grade 2, 40% (8/20) as grade 1. Of the 20 patients, 12 showed 
high expression (>66%), 4 low expression (<66%) and 4 no 
expression of estrogen receptor. The expression of progestin 
receptors was high (>66%) in 8 cases, low (<66%) in 6 cases, 
nothing in 6 cases. The score of c-erbB-2 was 3+ in 5 cases, 2+ 
in 2 cases, 1+ in 6 cases and 0 score in 7 samples. The expres-
sion of proliferation factor Ki67 was high (>20%) in 9 cases, 
and low (<20%) in 11 cases. 
The details of patients and tumor characteristics are shown 
in Table 1 and 2, and immunophenotype of fresh tubulolobular 
breast sample in Figure 1.
Expression of CD133 and CD44 in paraffin-embedded breast 
samples of fresh casuistry 
Expression of CD133 and CD44 was detected by immuno-
Table 1. Clinicopathological features of fresh samples
No. Age (yr) Histotype
Histologic 
grade
pN pT ER PR Ki67 HER2
  1 69 IDC G3 pN2 pT1 Neg Neg 40% 3+
  2 44 IDC G3 pN0 pT1 50% 45% 31% 1+
  3 58 IDC G3 pN1 pT2 Neg Neg 40% 3+
  4 40 IDC G2 pN1 pT1 75% 75% 15% 2+
  5 58 IDC G3 pN1 pT2 85% 85% 25% 2+
  6 46 MDLC G2 pN2 pT1 85% 85% 12% 1+
  7 44 IDC G3 pN0 pT2 40% Neg 57% 1+
  8 51 ITLC G1 pN0 pT1 85% 45% 5% 0
  9 68 IDC G2 pN0 pT1 85% 85% 10% 0
10 27 IDC G2 pN3 pT1 50% Neg 10% 3+
11 37 IDC G3 pN0 pT2 Neg Neg 45% 3+
12 85 IDC G3 pN0 pT1 85% 85% 25% 1+
ER=estrogen receptor; PR=progesterone receptor; IDC=infiltrant ductal car-
cinoma; Neg=negative; MDLC=mixed ductal and lobular carcinoma; 
ITLC=infiltrant tubulolobular carcinoma.18  MaurizioDiBonito,etal.
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histochemistry in 12 paraffin-embedded breast cancer speci-
mens. Also in this case the percentages of CD133
+ cells were 
very heterogeneous in all cases. In samples 5, 6, 9, 10, 11 the 
expression was very low or absent, while it was moderate (5/ 
15%) in samples 1, 2, 3, 4, 12 (Figure 2A and 2B). In case 7 the 
expression was >20% (Figure 2A and 2B) and only in tubu-
lolobular variant breast cancer the expression of CD133 was 
about 35% (Figure 3). 
Also for immunohistochemistry CD44 expression results 
were extremely variable (Figure 2A and 2B) and not very spe-
cific, also marking the normal component of breast tissues in 
examined samples (Figure 3).
Cell sorting of breast samples with regard to CSCs markers 
expression
FACS was performed using all fresh breast cancers. We ana-
lyzed the expression of CD133, CD44, CD326. The results 
showed that the mean percentage of CD133 positive cells was 
13.75% (range, 1.90-69.00%) while the mean percentage of 
CD44 positive cells was 17.90% (range, 2.30-52.30%). More-
over all cells analyzed were positive for CD326 (EpCAM), the 
antigen expressed on the basolateral surface of epithelial cells 
(data not shown). The flow cytometry analysis with regard to 
CD133 and CD44 expression is shown in Figure 2 and for     
tubulolobular sample in Figure 4. The percentages of CD133
+ 
cells were very heterogeneous between all examinated cases. 
In samples 4, 10, and 11 the percentage was very low for CD133
+ 
cells (3/7%), while in samples 1, 2, 3, 6, 7, 9, 12 was moderate 
(11/25%) (Figure 2A and 2B).
In tubulolobular breast variant the percentages of CD133
+ 
cells was very high, about 70% (Figure 4).
Only in one case (sample 5) the detection of CD133
+ cells 
from flow cytometry was absent, while in all cases analized 
the percentages of CD44
+ cells were extremely variable (Figure 
2 and 4).
CD133 mRNA quantification in fresh breast samples
CD133 gene expression was evaluated on all selected breast 
tissues by real-time PCR quantification. In samples 3, 4, 5, 6, 
10, 11 CD133 mRNA expression appeared very low or absent, 
while in 1, 2, 7, 9, 12 samples the expression was moderate 
(Figure 4).
Only in Tubulolobular breast specimen (sample 8) it was 
observed a significant increase in CD133 mRNA expression 
(Figure 5).
Expression of CD133 in archive breast tubulolobular variant 
samples
Expression of CD133 was detected by immunohistochemistry 
and real-time PCR quantification in 8 paraffin-embedded       
tubulolobular breast cancer specimens. Immunohistochemi-
cal detection shows a percentages of CD133
+ cells moderate in 
13 sample, very low in two cases 17 and 20, or absent in 14, 
15, 16, 18, 19 samples (Figure 6). 
CD133 gene expression was evaluated on selected breast tu-
bulolobular tissues by real-time PCR quantification.
In samples 13, 16, 17, 20 CD133 mRNA expression appeared 
very low while in 18 and 19 samples was absent (Figure 7).
Table 2. Clinicopathological features of archive samples
No.
Age 
(yr)
Istotype
Histologic 
grade
pN pT ER PR Ki67 HER2
13 56 ITLC G2  pN1 pT1 80% 40% 33% 0
14 51 ITLC G1 pN0 pT1 80% 85% 7% 0
15 46 ITLC G1 pN0 pT1 80% 30% 15% 0
16 42 ITLC G1 pN0 pT1 Neg Neg 25% 3+
17 56 ITLC G1 pN0 pT1 80% 80% 7% 1+
18 52 ITLC G1 pN1 pT1 80% 10% 5% 1+
19 61 ITLC G1 pN0 pT1 35% 85% 8% 0
20 58 ITLC G1 pN0 pT1 70% 10% 5% 0
ER=estrogen receptor; PR=progesterone receptor; ITLC=infiltrant tubulol-
obular carcinoma; Neg=negative.
Figure 1. Tubulolobular breast immunophenotype. (A) H&E morphology 
(×20). (B) immunopositivity for progesterone receptor (×60). (C) immu-
nopositivity for estrogen receptor (×60). (D) immunonegativity for HER2/
neu (×60). (E) immunopositivity for Ki67 (×60). (F) immunopositivity for 
E-Cadherin in ductal cells and immunonegativity in lobular cells (×60).
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D
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Figure 2A. CD133 and CD44 immunostaining: on the left in the first (CD133) and second (CD44) columns immunohistochemistry detection in sample 
1, 2, 3, 4, 5, 6 (×60); on the right in third (CD133) and fourth (CD44) columns histogram plot representation of flow cytometry detection in sample 1, 
2, 3, 4, 5, 6.
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Figure 2B. CD133 and CD44 immunostaining: on the left in the first (CD133) and second (CD44) columns immunohistochemistry detection in sam-
ples 7, 9, 10, 11, 12 (×60); on the right in third (CD133) and fourth (CD44) columns histogram plot representation of flow cytometry detection in sam-
ples 7, 9, 10, 11, 12.
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CD133 expression relates with Ki67 in breast cancers
From statistical elaboration of CD133 protein expression 
analysis with the other clinicopatological parameters in breast 
cancers selected for this study, it was shown that CD133 expres-
sion was significantly associated to Ki67 expression (p=0.010) 
(Table 3). 
Moreover, we detected an association between CD133 ex-
pression and ductal breast cancer histotype (p=0.049) and a 
trend of statistical correlation between CD133 expression and 
tumor grade (p=0.057) (Table 3).
DISCUSSION
In this paper we have evaluated the rise of CD133 antigen 
as a suitable marker for CSCs detection in breast carcinomas. 
The analysis was carried out by different methods, flow cyto- Prominin1inTubulobularBreastCarcinoma 21
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metry, immunohistochemistry and investigate CD133 gene           
expression by real-time PCR quantification. 
Our data were confirmed by all three methods, and the results 
are generally overlapping. Only in two cases the percentage of 
CD133-expressing cells detected by real-time PCR and flow 
cytometry, is found to be higher than that by immunohisto-
chemistry. 
There are possible explanations for the discordances be-
tween methods. First, fresh tumor tissue was used in the real-
time PCR and flow cytometry measurements and paraffin-
embedded tissue was used in immunohistochemistry. The 
staining pattern in the paraffin-embedded tissues could be     
altered by changes in tissue fixation conditions and antigen 
retrieval methods. Moreover, differences in immunostaining 
methodology, antibody concentrations, specificity of the anti-
bodies used to localize the protein, and antibody cross-reac-
tions must be considered [16]. 
All tumoral samples have a percentage of CD133 positive 
cells about 2-20%, except one tubulolobular breast variant that 
shows hyperexpression of the CSCs markers. 
Tubulolobular carcinoma is a rare subtype of mammary 
carcinoma, representing less than 3% of all breast cancers, ex-
hibiting features of both tubular and lobular differentiation. 
The prognosis of these tumors appears to be excellent, espe-
cially in those cases that are unilateral and less than 2 cm in 
size [17], and for this variant no information about the exis-
tence of stem cells detection was reported.
The hypothesis that mammary carcinogenesis results from 
the deregulation of normal stem cell self-renewal pathways 
suggests that components of these pathways might provide   
attractive targets for therapeutic development [18,19]. This 
idea is supported by recent description that the residual breast 
tumor cell populations surviving after conventional treatment 
Figure 3. CD133 and CD44 immunostaining in tubulolobular breast 
variant. (A) Immunopositivity for CD133 (×40). (B) immunopositivity for 
CD133 (×60). (C) immunopositivity for CD133 in tubular and lobular 
components (×60). (D) immunopositivity for CD44 (×60). (E) immuno-
negativity for CD133 in normal ductal cells (×40). (F) immunopositivity 
for CD44 in normal ductal cells (×40).
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Figure 4. CD133 and CD44 flow cytometry detection in tubulolobular 
breast variant. (A, C) Control. (B, D) CD133 expression in sample 8. (E, 
F) CD44 expression in sample 8.
A
C
o
u
n
t
PE-A
TN10-Tube_001
70
60
50
40
30
20
10
0
  10
2  10
3  10
4  10
5
C
P
E
-
A
FITC-A
TN10-Tube_001
10
5
10
4
10
3
10
2
  10
2  10
3  10
4  10
5
E
C
o
u
n
t
FITC-A
T-Tube_001
60
50
40
30
20
10
0
  10
2  10
3  10
4  10
5
B
C
o
u
n
t
CD133 PE-A
TN10-Tube_004
60
50
40
30
20
10
0
  10
2  10
3  10
4  10
5
D
C
D
1
3
3
 
P
E
-
A
CD44 FITC-A
TN10-Tube_003
10
5
10
4
10
3
10
2
  10
2  10
3  10
4  10
5
F
C
o
u
n
t
CD44 FITC-A
TN10-Tube_002
100
75
50
25
0
  10
2  10
3  10
4  10
5
Figure 5. Prominin-1/CD133 real-time expression in breast samples. All 
reactions were performed in triplicate and data are expressed as mean 
of relative amount of mRNAs levels.
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may be enriched for subpopulations of cells with self-renewal 
features [5].
In the last years it was shown that the elective cancer stem 
cell marker for breast tumors is Prominin-1 which expression 
is not only strongly associated to stem cell phenotype but also 
to prognosis in invasive ductal breast cancer [14,15].
The possibility of targeting breast CSCs by CD133 inhibi-
tion provides a novel therapeutic approach for treatment of 
breast tumors [20]. 
In this study we show the strong overlap between gene and 
protein expression of CD133 marker in breast carcinomas. This 
might suggest the possibility of perturbing CD133 expression 
at transcription level, as decribed in malignant melanoma, 
where the shRNA-mediated downregulation results in altera-
tion in cell growth and mobility, and reduces the capacity to 
metastatize in vivo [21], and at proteic level as previously shown 
in hepatocellular and gastric cancer xenografts [22].
Since there are no indications concerning the presence of 
Figure 6. CD133 immunostaining in archive tubulolobular breast vari-
ant. (13, 17, 20) immunopositivity for CD133 (×40). (14, 15, 16, 18, 19) 
immunonegativity for CD133 (×40).
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Table 3. Relation between CD133 and clinicopathological characteris-
tics of breast cancer patients
Clinicopathological 
features
CD133
-/Low
No. (%)
Moderate
No. (%)
High
No. (%)
p-value
Age (yr)
   ≤40 2 (100) 0 0
   >40, ≤60 3 (50) 3 (50) 0 0.662
   >60 7 (58.3) 4 (33.1) 1 (8.3)
Histotype
   IDC 4 (36.3) 7 (63.7) 0
   MDLC 1 (100) 0 0 0.049
   ITLC 7 (87.5) 0 1 (12.5)
pN
   0   8 (66.7) 3 (25) 1 (8.3)
   1 2 (40) 3 (60) 0 0.796
   2 1 (50) 1 (50) 0
   3    1 (100) 0 0
pT
   1 10 (62.5) 5 (31.25) 1 (5.25) 0.721
   2 2 (50) 2 (50) 0
Grade
   I 7 (87.5) 0 1 (12.5)
   II 3 (60) 2 (40) 0 0.057
   III 2 (28.6) 5 (71.4) 0
ER
   Negative 2 (50) 2 (50) 0
   Moderate 0 0 0 0.721
   High  10 (62.5) 5 (31.3) 1 (8.2)
PR
   Negative 3 (50) 3 (50) 0
   Moderate 2 (100) 0 0 0.662
   High  7 (58.3) 4 (33.3) 1 (8.3)
HER2/neu
   0 5 (71.4) 1 (14.3) 1 (14.3)
   1+ 3 (50) 3 (50) 0 0.737
   2+ 1 (50) 1 (50) 0
   3+ 3 (60) 2 (40) 0
Ki67
   Low 8 (88.9) 0 1 (11.1) 0.010
   High 4 (36.4) 7 (63.6) 0
IDC=infiltrant ductal carcinoma; MDLC=mixed ductal and lobular carcinoma; 
ITLC=infiltrant tubulolobular carcinoma; ER=estrogen receptor; PR= 
progesterone receptor.
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Figure 7. Prominin-1/CD133 real-time expression in archive tubulolobu-
lar breast samples. All reactions were performed in triplicate and data 
are expressed as mean of relative amount of mRNAs levels.Prominin1inTubulobularBreastCarcinoma 23
http://dx.doi.org/10.4048/jbc.2012.15.1.15  http://ejbc.kr
stem cells compartments in tumors with good prognosis such 
as tubulolobular variant of breast cancer, our data suggest the 
importance of detecting stem cell niches, by CD133, in all 
phenotypic variants of breast carcinomas, to define prognostic 
value of these cells, as well as to establish novel therapeutic 
strategies targeted cancer stem cell self-renewal. 
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